US 12,357,619 B2
Noradrenergic and specific serotonergic anxiolytic and antidepressant, method for the production and use thereof
Alexandre Vasilievich Ivachtchenko, Hallandale Beach, FL (US); and Andrey Alexandrovich Ivashchenko, Moscow (RU)
Assigned to ALLA CHEM LLC, Hallandale, FL (US); Alena Alexandrovna Ivachtechenko, Hallandale, FL (US); and Nikolay Filippovich Savchuk, Rancho Santa Fe, CA (US)
Appl. No. 16/767,155
Filed by ALLA CHEM, LLC, Hallandale, FL (US); Alena Alexandrovna Ivachtchenko, Hallandale, FL (US); and Nikolay Filippovich Savchuk, Rancho Santa Fe, CA (US)
PCT Filed Mar. 27, 2020, PCT No. PCT/RU2020/000161
§ 371(c)(1), (2) Date Jun. 26, 2023,
PCT Pub. No. WO2021/187997, PCT Pub. Date Sep. 23, 2021.
Claims priority of application No. 2020111367 (RU), filed on Mar. 19, 2020.
Prior Publication US 2024/0238260 A1, Jul. 18, 2024
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/437 (2013.01) [A61P 25/22 (2018.01); A61P 25/24 (2018.01); C07D 471/04 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising a polymorphic form CF1 of 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), wherein CF1 exhibits at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu Kα radiation at 10.2±0.2, 16.8±0.2, 19.3±0.2, 24.9±0.2, and 25.3±0.2.